Visual Performance With Spatial Light Modulator

NCT ID: NCT05134896

Last Updated: 2021-11-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-30

Study Completion Date

2023-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Eye's aberrations have been known to degrade human visual performance and the visual performance is significantly improved when correcting the aberrations in the central visual field. However, how the aberration correction affects the peripheral visual performance is not well understood. Moreover, how central and peripheral vision interacts remains unclear.

To conduct the study, we will use an adaptive optics vision simulator equipped with a Shack-Hartmann wavefront sensor and a spatial light modulator (see details in procedures section of the protocol). This system is capable of noninvasively controlling the eye's optical quality and evaluating visual performance simultaneously over a wide area of visual space. This study provides insights into the visual performance in the periphery visual field, and interaction between central and peripheral visual fields.

The goal of this study is to evaluate the visual performance at central and peripheral visual fields after correcting the ocular aberrations. An optical system equipped with a liquid crystal spatial light modulator will be used to achieve this goal non-invasively.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Normal Healthy Eyes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

normal healthy group

Spatial light modulator

Group Type EXPERIMENTAL

Spatial light modulator

Intervention Type DEVICE

This device compensates for the eye's optical imperfections (aberrations) at the foveal and peripheral retina.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Spatial light modulator

This device compensates for the eye's optical imperfections (aberrations) at the foveal and peripheral retina.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

A person is eligible for inclusion in the study if he/she:

* Is between the ages of 18 and 60.
* Has normal corneas i.e. no corneal infections, no systemic pink eye, no clinically significant dry eye, and no corneal dystrophies.
* Has refractive errors less than +/- 10.0 Diopters in both eyes.

Exclusion Criteria

A person will be excluded from the study if he/she:

* Adults between the ages of 18-60 who are unable to give informed consent
* Individuals below 18 years old
* Individuals above the age of 60
* Pregnant women (self-reporting, hormonal changes may alter the refractive status of the eye)
* Prisoners
* Students for whom you have direct access to/influence on grades
* People who do not understand or speak English
* Has clinically significant dry eye.
* Has clinically significant cataract.
* Has spherical refractive error that exceeds the limits outlined above.
* Is unable to hold his or her head steady for the duration of study measurements.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Houston

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Geunyoung Yoon

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Geunyoung Yoon, PhD

Role: CONTACT

Phone: 7137437860

Email: [email protected]

Jiakai Lyu, MS

Role: CONTACT

Phone: 6262953929

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STUDY00003209

Identifier Type: -

Identifier Source: org_study_id